Gantenerumab + Gantenerumab + Gantenerumab + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease
Trial Timeline
Jun 1, 2012 → Jun 1, 2014
NCT ID
NCT01656525About Gantenerumab + Gantenerumab + Gantenerumab + Placebo
Gantenerumab + Gantenerumab + Gantenerumab + Placebo is a phase 1 stage product being developed by Chugai Pharmaceutical for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01656525. Target conditions include Alzheimer's Disease.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer's Disease were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01656525 | Phase 1 | Completed |
Competing Products
20 competing products in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| GSK4527226 | Alector | Phase 2 | 29 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 44 |
| solanezumab | Eli Lilly | Phase 2 | 35 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 29 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 39 |
| FK962 | Astellas Pharma | Phase 2 | 27 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 29 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 32 |
| Donepezil | Eisai | Approved | 43 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride | Eisai | Phase 3 | 40 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 26 |
| Lecanemab IV + Placebo + Lecanemab SC | Eisai | Phase 3 | 44 |